VEGF

Summit
Biotech

AstraZeneca scales Summit’s PD-1xVEGF combos with $2B investment

AstraZeneca is investing $2 billion in Summit to accelerate the development of PD-1xVEGF bispecific ivonescimab in combination with ADCs.
Nick Paul Taylor Sep 29, 2026 3:07am
Close up of amber eye

Kodiak's stock doubles with win for resurrected eye disease drug

Sep 28, 2026 8:37am
Glowing puzzle piece fitting into puzzle

AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF race

Jan 12, 2026 11:00am
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm
BioNTech

BioNTech, BMS tout first global data for PD-L1xVEGF drug in SCLC

Sep 8, 2025 11:00am